Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1997 2
2001 1
2002 1
2005 2
2006 2
2007 1
2010 2
2011 1
2013 1
2015 8
2016 7
2017 8
2018 8
2019 6
2020 2
2021 3
2022 3
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for james nras
Search for James Noras instead (2 results)
ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
Eichhoff OM, Stoffel CI, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng PF, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan VS, Wenzina J, Aloia A, Saltari A, Dzung A; TuPro Consortium; Krauthammer M, Schreiber SL, Hornemann T, Distel M, Snijder B, Dummer R, Levesque MP. Eichhoff OM, et al. Cancer Res. 2023 Apr 4;83(7):1128-1146. doi: 10.1158/0008-5472.CAN-22-1826. Cancer Res. 2023. PMID: 36946761
Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of patients due to resistance that arises through genetic, transcriptional, and metabolic adaptation. Identification of targetable vulnerabili …
Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of …
Whole-genome landscapes of major melanoma subtypes.
Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ. Hayward NK, et al. Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3. Nature. 2017. PMID: 28467829
The number of genes affected by recurrent mutations disrupting non-coding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in …
The number of genes affected by recurrent mutations disrupting non-coding sequences was similar to that affected by recurrent mutations to c …
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Walker BA, et al. J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282654 Free PMC article. Clinical Trial.
RESULTS: We identified 15 significantly mutated genes: IRF4, KRAS, NRAS, MAX, HIST1H1E, RB1, EGR1, TP53, TRAF3, FAM46C, DIS3, BRAF, LTB, CYLD, and FGFR3. ...
RESULTS: We identified 15 significantly mutated genes: IRF4, KRAS, NRAS, MAX, HIST1H1E, RB1, EGR1, TP53, TRAF3, FAM46C, DIS3, BRAF, L …
Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study.
Niehues JM, Quirke P, West NP, Grabsch HI, van Treeck M, Schirris Y, Veldhuizen GP, Hutchins GGA, Richman SD, Foersch S, Brinker TJ, Fukuoka J, Bychkov A, Uegami W, Truhn D, Brenner H, Brobeil A, Hoffmeister M, Kather JN. Niehues JM, et al. Cell Rep Med. 2023 Apr 18;4(4):100980. doi: 10.1016/j.xcrm.2023.100980. Epub 2023 Mar 22. Cell Rep Med. 2023. PMID: 36958327 Free PMC article.
We systematically compare six different state-of-the-art DL architectures to predict biomarkers from pathology slides, including MSI and mutations in BRAF, KRAS, NRAS, and PIK3CA. Using a large external validation cohort to provide a realistic evaluation setting, we show t …
We systematically compare six different state-of-the-art DL architectures to predict biomarkers from pathology slides, including MSI and mut …
Nerve root anomalies: making sense of a complicated literature.
Schmidt CK, Rustagi T, Alonso F, Loukas M, Chapman JR, Oskouian RJ, Tubbs RS. Schmidt CK, et al. Childs Nerv Syst. 2017 Aug;33(8):1261-1273. doi: 10.1007/s00381-017-3457-3. Epub 2017 Jun 16. Childs Nerv Syst. 2017. PMID: 28623517 Review.
INTRODUCTION: Nerve root anomalies (NRAs) are a set of well-described congenital irregularities for which several classification systems have been devised over the years. CONCLUSION: This comprehensive review examines the anatomy and characteristics of NRAs; their s …
INTRODUCTION: Nerve root anomalies (NRAs) are a set of well-described congenital irregularities for which several classification syst …
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P, Lee LC, Han M, Matthews JD, Jahangiri L, Schlederer M, Manners E, Sorby-Adams A, Kaggie J, Trigg RM, Steel C, Hare L, James ER, Prokoph N, Ducray SP, Merkel O, Rifatbegovic F, Luo J, Taschner-Mandl S, Kenner L, Burke GAA, Turner SD. Pucci P, et al. Nat Commun. 2024 Apr 23;15(1):3422. doi: 10.1038/s41467-024-47771-x. Nat Commun. 2024. PMID: 38653965 Free PMC article.
Using high-throughput, genome-wide CRISPR-Cas9 knockout screens, we identify miR-1304-5p loss as a desensitizer to ALK TKIs in aberrant ALK-expressing neuroblastoma; inhibition of miR-1304-5p decreases, while mimics of this miRNA increase the sensitivity of neuroblastoma cells to …
Using high-throughput, genome-wide CRISPR-Cas9 knockout screens, we identify miR-1304-5p loss as a desensitizer to ALK TKIs in aberrant ALK- …
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Cibula D, Moore KN, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Kristensen G, Clamp A, Farley J, Iyer G, Ray-Coquard I, Monk BJ. Grisham RN, et al. Clin Cancer Res. 2023 Oct 13;29(20):4068-4075. doi: 10.1158/1078-0432.CCR-23-0621. Clin Cancer Res. 2023. PMID: 37581616 Free PMC article.
In 135 patients treated with binimetinib with response rate (RR) data, other detected MAPK pathway alterations included: NRAS (n = 11, 8.1%), BRAF V600E (n = 8, 5.9%), RAF1 (n = 2, 1.5%), and NF1 (n = 7, 5.2%). ...
In 135 patients treated with binimetinib with response rate (RR) data, other detected MAPK pathway alterations included: NRAS (n = 11 …
Global regulatory reforms to promote equitable vaccine access in the next pandemic.
Mahoney R, Hotez PJ, Bottazzi ME. Mahoney R, et al. PLOS Glob Public Health. 2023 Oct 18;3(10):e0002482. doi: 10.1371/journal.pgph.0002482. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 37851688 Free PMC article. Review.
In addition to expanding support for academic or non-profit product development partnerships, our analysis finds that an essential step is the strengthening of selected LMIC regulatory systems to become Stringent Regulatory Authorities (SRAs), together with a re-prioritization of …
In addition to expanding support for academic or non-profit product development partnerships, our analysis finds that an essential step is t …
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others.
Bupathi M, Wu C. Bupathi M, et al. J Gastrointest Oncol. 2016 Oct;7(5):713-720. doi: 10.21037/jgo.2016.07.03. J Gastrointest Oncol. 2016. PMID: 27747085 Free PMC article. Review.
Molecular testing is now routinely performed to select for patients that will benefit the most from targeted agents and immunotherapy. In addition to KRAS, NRAS, and BRAF mutation (MT), analysis of DNA mismatch repair (MMR) status, tumor infiltrating lymphocytes, and check …
Molecular testing is now routinely performed to select for patients that will benefit the most from targeted agents and immunotherapy. In ad …
61 results